Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma
Using tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on clinicopathological correlations and the outcome of patients with malignant melanoma (MM). TMA-1 contained normal and tumor tissues (n=3448) from 47 organs including skin neoplasms (n=32...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2010/848645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561117483761664 |
|---|---|
| author | Stefanie Meyer Thomas Vogt Michael Landthaler Anna Berand Albrecht Reichle Frauke Bataille Andreas H. Marx Anne Menz Arndt Hartmann Leoni A. Kunz-Schughart Peter J. Wild |
| author_facet | Stefanie Meyer Thomas Vogt Michael Landthaler Anna Berand Albrecht Reichle Frauke Bataille Andreas H. Marx Anne Menz Arndt Hartmann Leoni A. Kunz-Schughart Peter J. Wild |
| author_sort | Stefanie Meyer |
| collection | DOAJ |
| description | Using tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on clinicopathological correlations and the outcome of patients with malignant melanoma (MM).
TMA-1 contained normal and tumor tissues (n=3448) from 47 organs including skin neoplasms (n=323); TMA-2 88 primary MM, 101 metastases, and 161 benign nevi. Based on a biomodulatory approach combining COX/PPAR-targeting with metronomic low-dose chemotherapy metastases of 36 patients participating in a randomized trial with metastatic (stage IV) melanoma were investigated using TMA-3. COX2/PPARG immunoreactivity significantly increased from nevi to primary MM and metastases; COX2 positivity was associated with advanced Clark levels and shorter recurrence-free survival. Patients with PPARG-positive metastases and biomodulatory metronomic chemotherapy alone or combined with COX2/PPARG-targeting showed a significantly prolonged progression-free survival. Regarding primary MM, COX2 expression indicates an increased risk of tumor recurrence. In metastatic MM, PPARG expression may be a predicitive marker for response to biomodulatory stroma-targeted therapy. |
| format | Article |
| id | doaj-art-d91515f1f7bf433a908c5ef02b3b7b41 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-d91515f1f7bf433a908c5ef02b3b7b412025-02-03T01:25:54ZengWileyPPAR Research1687-47571687-47652010-01-01201010.1155/2010/848645848645Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant MelanomaStefanie Meyer0Thomas Vogt1Michael Landthaler2Anna Berand3Albrecht Reichle4Frauke Bataille5Andreas H. Marx6Anne Menz7Arndt Hartmann8Leoni A. Kunz-Schughart9Peter J. Wild10Department of Dermatology, University of Regensburg, 93042 Regensburg, GermanyDepartment of Dermatology, University of Regensburg, 93042 Regensburg, GermanyDepartment of Dermatology, University of Regensburg, 93042 Regensburg, GermanyDepartment of Hematology and Oncology, University of Regensburg, 93042 Regensburg, GermanyDepartment of Hematology and Oncology, University of Regensburg, 93042 Regensburg, GermanyInstitute of Pathology, University of Regensburg, 93042 Regensburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyInstitute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyInstitute of Clinical Pathology, University of Erlangen, 91054 Erlangen, GermanyOncoRay - Center for Radiation Research in Oncology, TU Dresden, 01307 Dresden, GermanyInstitute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, SwitzerlandUsing tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on clinicopathological correlations and the outcome of patients with malignant melanoma (MM). TMA-1 contained normal and tumor tissues (n=3448) from 47 organs including skin neoplasms (n=323); TMA-2 88 primary MM, 101 metastases, and 161 benign nevi. Based on a biomodulatory approach combining COX/PPAR-targeting with metronomic low-dose chemotherapy metastases of 36 patients participating in a randomized trial with metastatic (stage IV) melanoma were investigated using TMA-3. COX2/PPARG immunoreactivity significantly increased from nevi to primary MM and metastases; COX2 positivity was associated with advanced Clark levels and shorter recurrence-free survival. Patients with PPARG-positive metastases and biomodulatory metronomic chemotherapy alone or combined with COX2/PPARG-targeting showed a significantly prolonged progression-free survival. Regarding primary MM, COX2 expression indicates an increased risk of tumor recurrence. In metastatic MM, PPARG expression may be a predicitive marker for response to biomodulatory stroma-targeted therapy.http://dx.doi.org/10.1155/2010/848645 |
| spellingShingle | Stefanie Meyer Thomas Vogt Michael Landthaler Anna Berand Albrecht Reichle Frauke Bataille Andreas H. Marx Anne Menz Arndt Hartmann Leoni A. Kunz-Schughart Peter J. Wild Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma PPAR Research |
| title | Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma |
| title_full | Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma |
| title_fullStr | Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma |
| title_full_unstemmed | Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma |
| title_short | Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma |
| title_sort | cyclooxygenase 2 cox2 and peroxisome proliferator activated receptor gamma pparg are stage dependent prognostic markers of malignant melanoma |
| url | http://dx.doi.org/10.1155/2010/848645 |
| work_keys_str_mv | AT stefaniemeyer cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT thomasvogt cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT michaellandthaler cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT annaberand cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT albrechtreichle cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT fraukebataille cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT andreashmarx cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT annemenz cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT arndthartmann cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT leoniakunzschughart cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma AT peterjwild cyclooxygenase2cox2andperoxisomeproliferatoractivatedreceptorgammappargarestagedependentprognosticmarkersofmalignantmelanoma |